Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2019 | Nov. 12, 2019 | |
Cover [Abstract] | ||
Entity Registrant Name | Tiberius Acquisition Corp | |
Entity Central Index Key | 0001662253 | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Shell Company | true | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Common Stock, Shares Outstanding | 21,562,500 | |
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Sep. 30, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q3 | |
Entity Address, State or Province | LA |
CONDENSED BALANCE SHEETS (Unaud
CONDENSED BALANCE SHEETS (Unaudited) - USD ($) | Sep. 30, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash | $ 56,180 | $ 325,115 |
Income tax receivable | 20,000 | 30,000 |
Prepaid expenses | 69,825 | 114,725 |
Total current assets | 146,005 | 469,840 |
Investments and cash held in trust account | 178,739,627 | 176,444,379 |
Total assets | 178,885,632 | 176,914,219 |
Current liabilities: | ||
Accounts payable and accrued expenses | 103,608 | 184,237 |
Due to sponsor | 95,000 | 5,000 |
Total current liabilities | 198,608 | 189,237 |
Sponsor loan payable | 1,875,000 | 1,725,000 |
Deferred underwriting commissions | 7,350,000 | 7,350,000 |
Total liabilities | 9,423,608 | 9,264,237 |
Commitments: | ||
Common stock subject to possible redemption; $0.0001 par value; 15,871,770 shares (at redemption value of approximately $10.36 per share) as of September 30, 2019 and 15,914,128 shares (at redemption value of approximately $10.22 per share) as of December 31, 2018 | 164,462,023 | 162,649,981 |
Stockholders' equity: | ||
Preferred stock, $0.0001 par value, 1,000,000 shares authorized, none issued or outstanding | 0 | 0 |
Common stock, $0.0001 par value, 60,000,000 shares authorized, 5,690,730 shares issued and outstanding (excluding 15,871,770 shares subject to possible redemption) as of September 30, 2019 and 5,648,372 issued and outstanding (excluding 15,914,128 shares subject to possible redemption) as of December 31, 2018 | 569 | 565 |
Additional paid-in-capital | 1,625,077 | 3,437,124 |
Retained earnings | 3,374,355 | 1,562,312 |
Total stockholders' equity | 5,000,001 | 5,000,001 |
Total liabilities and stockholders' equity | $ 178,885,632 | $ 176,914,219 |
CONDENSED BALANCE SHEETS (Una_2
CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares | Sep. 30, 2019 | Dec. 31, 2018 |
LIABILITIES AND STOCKHOLDERS' EQUITY: | ||
Common stock subject to possible redemption, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock subject to possible redemption, shares (in shares) | 15,871,770 | 15,914,128 |
Common stock, redemption value (in dollars per share) | $ 10.36 | $ 10.22 |
Stockholders' equity: | ||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, authorized shares (in shares) | 1,000,000 | 1,000,000 |
Preferred stock, issued shares (in shares) | 0 | 0 |
Preferred stock, outstanding shares (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 60,000,000 | 60,000,000 |
Common stock, shares issued (in shares) | 5,690,730 | 5,648,372 |
Common stock, shares outstanding (in shares) | 5,690,730 | 5,648,372 |
CONDENSED STATEMENTS OF OPERATI
CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | ||
CONDENSED STATEMENTS OF OPERATIONS (Unaudited) [Abstract] | |||||
General and administrative expenses | $ (333,527) | $ (181,591) | $ (739,053) | $ (459,342) | |
Loss from operations | (333,527) | (181,591) | (739,053) | (459,342) | |
Interest income | 968,144 | 867,843 | 3,039,791 | 1,728,386 | |
Unrealized (loss) gain on marketable securities | (66,163) | (54,048) | 23,305 | (44,313) | |
Other income, net | 901,981 | 813,795 | 3,063,096 | 1,684,073 | |
Net income before taxes | 568,454 | 632,204 | 2,324,043 | 1,224,731 | |
Provision for income taxes | 162,000 | 132,500 | 512,000 | 253,000 | |
Net income | $ 406,454 | $ 499,704 | $ 1,812,043 | $ 971,731 | |
Weighted average number of shares outstanding: | |||||
Basic and diluted (in shares) | [1] | 5,667,754 | 5,629,138 | 5,658,379 | 5,239,246 |
Loss available to common shares: | |||||
Basic and diluted (in dollars per share) | [2] | $ (0.04) | $ (0.02) | $ (0.08) | $ (0.04) |
[1] | Excludes an aggregate of 15,871,770 and 15,924,510 shares subject to redemption at September 30, 2019 and 2018, respectively. | ||||
[2] | Net loss per common share - basic and diluted excludes interest income attributable to common stock subject redemption of $643,594 and $589,444 for the three months ended September 30, 2019 and 2018, respectively, and $2,245,187 and $1,202,610 for the nine months ended September 30, 2019 and 2018, respectively. |
CONDENSED STATEMENTS OF OPERA_2
CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - USD ($) | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Weighted average number of shares outstanding: | ||
Common stock subject to possible redemption, shares (in shares) | 15,871,770 | 15,924,510 |
Loss available to common shares: | ||
Net loss per common share - basic and diluted excludes interest income attributable to common stock | $ 2,245,187 | $ 1,202,610 |
CONDENSED STATEMENTS OF CHANGES
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings (Accumulated Deficit) [Member] | Total |
Balance at Beginning at Dec. 31, 2017 | $ 431 | $ 24,569 | $ (19,230) | $ 5,770 |
Balance at Beginning (in shares) at Dec. 31, 2017 | 4,312,500 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Sale of common stock to public, net of offering costs | $ 1,725 | 161,560,945 | 0 | 161,562,670 |
Sale of common stock to public, net of offering costs (in shares) | 17,250,000 | |||
Sale of 4,500,000 Private Placement Warrants | $ 0 | 4,500,000 | 0 | 4,500,000 |
Change in value of common stock subject to possible redemption | $ (1,594) | (161,079,231) | 0 | (161,080,825) |
Change in value of common stock subject to possible redemption (in shares) | (15,945,041) | |||
Net income | $ 0 | 0 | 12,386 | 12,386 |
Balance at End at Mar. 31, 2018 | $ 562 | 5,006,283 | (6,844) | 5,000,001 |
Balance at End (in shares) at Mar. 31, 2018 | 5,617,459 | |||
Balance at Beginning at Dec. 31, 2017 | $ 431 | 24,569 | (19,230) | 5,770 |
Balance at Beginning (in shares) at Dec. 31, 2017 | 4,312,500 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Net income | 971,731 | |||
Balance at End at Sep. 30, 2018 | $ 564 | 4,046,936 | 952,501 | 5,000,001 |
Balance at End (in shares) at Sep. 30, 2018 | 5,637,990 | |||
Balance at Beginning at Mar. 31, 2018 | $ 562 | 5,006,283 | (6,844) | 5,000,001 |
Balance at Beginning (in shares) at Mar. 31, 2018 | 5,617,459 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Change in value of common stock subject to possible redemption | $ 1 | (459,642) | 0 | (459,641) |
Change in value of common stock subject to possible redemption (in shares) | 11,679 | |||
Net income | $ 0 | 0 | 459,641 | 459,641 |
Balance at End at Jun. 30, 2018 | $ 563 | 4,546,641 | 452,797 | 5,000,001 |
Balance at End (in shares) at Jun. 30, 2018 | 5,629,138 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Change in value of common stock subject to possible redemption | $ 1 | (499,705) | 0 | (499,704) |
Change in value of common stock subject to possible redemption (in shares) | 8,852 | |||
Net income | $ 0 | 0 | 499,704 | 499,704 |
Balance at End at Sep. 30, 2018 | $ 564 | 4,046,936 | 952,501 | 5,000,001 |
Balance at End (in shares) at Sep. 30, 2018 | 5,637,990 | |||
Balance at Beginning at Dec. 31, 2018 | $ 565 | 3,437,124 | 1,562,312 | $ 5,000,001 |
Balance at Beginning (in shares) at Dec. 31, 2018 | 5,648,372 | 5,648,372 | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Change in value of common stock subject to possible redemption | $ 1 | (642,941) | 0 | $ (642,940) |
Change in value of common stock subject to possible redemption (in shares) | 10,426 | |||
Net income | $ 0 | 0 | 642,940 | 642,940 |
Balance at End at Mar. 31, 2019 | $ 566 | 2,794,183 | 2,205,252 | 5,000,001 |
Balance at End (in shares) at Mar. 31, 2019 | 5,658,798 | |||
Balance at Beginning at Dec. 31, 2018 | $ 565 | 3,437,124 | 1,562,312 | $ 5,000,001 |
Balance at Beginning (in shares) at Dec. 31, 2018 | 5,648,372 | 5,648,372 | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Sale of common stock to public, net of offering costs (in shares) | 17,250,000 | |||
Net income | $ 1,812,043 | |||
Balance at End at Sep. 30, 2019 | $ 569 | 1,625,077 | 3,374,355 | $ 5,000,001 |
Balance at End (in shares) at Sep. 30, 2019 | 5,690,730 | 5,690,730 | ||
Balance at Beginning at Mar. 31, 2019 | $ 566 | 2,794,183 | 2,205,252 | $ 5,000,001 |
Balance at Beginning (in shares) at Mar. 31, 2019 | 5,658,798 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Change in value of common stock subject to possible redemption | $ 1 | (762,650) | 0 | (762,649) |
Change in value of common stock subject to possible redemption (in shares) | 8,956 | |||
Net income | $ 0 | 0 | 762,649 | 762,649 |
Balance at End at Jun. 30, 2019 | $ 567 | 2,031,533 | 2,967,901 | 5,000,001 |
Balance at End (in shares) at Jun. 30, 2019 | 5,667,754 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Change in value of common stock subject to possible redemption | $ 2 | (406,456) | 0 | (406,454) |
Change in value of common stock subject to possible redemption (in shares) | 22,976 | |||
Net income | $ 0 | 0 | 406,454 | 406,454 |
Balance at End at Sep. 30, 2019 | $ 569 | $ 1,625,077 | $ 3,374,355 | $ 5,000,001 |
Balance at End (in shares) at Sep. 30, 2019 | 5,690,730 | 5,690,730 |
CONDENSED STATEMENTS OF CHANG_2
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical) | 3 Months Ended |
Mar. 31, 2018shares | |
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) [Abstract] | |
Private placement warrants sold (in shares) | 4,500,000 |
CONDENSED STATEMENTS OF CASH FL
CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Cash flows from operating activities: | ||
Net income | $ 1,812,043 | $ 971,731 |
Adjustments to reconcile net income to cash used in operating activities: | ||
Interest earned in Trust Account | (3,039,791) | (1,728,386) |
Unrealized gains on marketable securities held in Trust Account | (23,305) | 44,313 |
Changes in operating assets and liabilities: | ||
Changes in prepaid expenses and other current assets | 44,900 | (140,825) |
Changes in accounts payable and accrued expenses | 9,370 | 104,079 |
Changes in income taxes payable | 10,000 | 253,000 |
Net cash used in operating activities | (1,186,783) | (496,088) |
Cash flows from investing activities: | ||
Cash deposited in Trust Account | 0 | (174,225,000) |
Interest income released from Trust Account for tax payments | 767,848 | 0 |
Net cash provided by (used in) investing activities | 767,848 | (174,225,000) |
Cash flows from financing activities: | ||
Proceeds from sale of Units in Public Offering | 0 | 169,500,000 |
Proceeds from Sponsor Loan | 150,000 | 1,725,000 |
Proceeds from sale of Private Placement Warrants | 0 | 4,500,000 |
Note payable borrowings | 0 | 45,437 |
Repayment of Note payable borrowings | 0 | (250,000) |
Advance from Sponsor | 0 | 74,540 |
Repayment of Advance from Sponsor | 0 | (69,540) |
Payment of offering costs | 0 | (364,311) |
Net cash provided by financing activities | 150,000 | 175,161,126 |
Net change in cash | (268,935) | 440,038 |
Cash at beginning of period | 325,115 | 5,347 |
Cash at end of period | 56,180 | 445,385 |
Supplementary cash flow information: | ||
Cash paid for taxes | 502,000 | 0 |
Non-cash investing and financing activities: | ||
Deferred underwriting commissions | 0 | 7,350,000 |
Initial value of common shares subject to possible redemption | 0 | 161,033,395 |
Change in value of common shares subject to possible redemption | $ 1,812,042 | $ 1,006,775 |
DESCRIPTION OF ORGANIZATION AND
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS | 9 Months Ended |
Sep. 30, 2019 | |
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS [Abstract] | |
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS | NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Organization and General: Tiberius Acquisition Corporation (the ‘‘Company’’) was incorporated in Delaware on November 18, 2015. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the ‘‘Business Combination’’). While it may pursue an acquisition opportunity in any business industry or sector and in any geographic region, the Company expects to focus on the U.S. based middle-market insurance sector. The Company has entered into a Business Combination Agreement with International General Insurance Holdings Ltd., as discussed in Note 9 below. All activity through March 15, 2018, consisted of formation and preparation for the Public Offering. Since the Public Offering, the Company’s activity has been limited to the evaluation of business combination candidates, including International General Insurance Holdings Ltd., and the Company has not generated and will not be generating any operating revenues until the closing of its initial business combination. The Company generates non-operating income in the form of interest on marketable securities held in the trust account. The Company is incurring expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence and transaction expenses. The registration statement for the Company’s Public Offering was declared effective on March 15, 2018. On March 20, 2018, the Company consummated the Public Offering of 15,000,000 units (“Units” and, with respect to the common stock included in the Units sold, the “Public Shares”) generating gross proceeds of $150,000,000, which is described in Note 3. Simultaneously with the closing of the Public Offering, the Company consummated the sale of 4,500,000 warrants at a price of $1.00 per warrant (“Placement Warrants”) in a private placement to Lagniappe Ventures LLC (the “Sponsor”) generating gross proceeds of $4,500,000 (“Private Placement”), which is described in Note 4. Simultaneously with the closing of the Public Offering, the Company received a loan from the Sponsor in the amount of $1,500,000 (“Sponsor Loan”), which is described in Note 4. Following the closing of the Public Offering on March 20, 2018, an amount of $151,500,000 ($10.10 per Unit) from the net proceeds of the Public Offering, Placement Warrants, and Sponsor Loan were placed in a trust account (“Trust Account”) which may be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of the initial Business Combination or (ii) the distribution of the Trust Account, as described below, except that interest earned on the Trust Account can be released to the Company to pay its tax obligations. On March 28, 2018, in connection with the underwriters’ exercise of their over-allotment option in full, the Company consummated the sale of an additional 2,250,000 Units at $10.00 per Unit, and the Company received a loan from the Sponsor in the amount of $225,000. Following the closing, an additional $22,725,000 of net proceeds was placed in the Trust Account. Transaction costs amounted to $10,937,331, consisting of $3,000,000 of underwriting fees, $7,350,000 of deferred underwriting fees and $587,331 of Public Offering costs. In addition, $1,278,124 of cash held outside of the Trust Account upon closing of the Initial Public Offering was available for working capital purposes immediately following the Public Offering. Business Combination: The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds of the Public Offering are intended to be generally applied toward consummating a Business Combination with a Target Business (discussed below). As used herein, ‘‘Target Business’’ must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the trust account (less any deferred underwriting commissions and taxes payable on interest earned) at the time of signing a definitive agreement in connection with the Company’s initial Business Combination in accordance NASDAQ listing rules. There is no assurance that the Company will be able to successfully effect a Business Combination. The Company, after signing a definitive agreement for a Business Combination, will either (i) seek stockholder approval of the Business Combination at a meeting called for such purpose in connection with which stockholders may seek to redeem their shares, regardless of whether they vote for or against the Business Combination, for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account as of two business days prior to the consummation of the initial Business Combination, including interest but less taxes payable, or (ii) provide stockholders with the opportunity to sell their shares to the Company by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount in cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account as of two business days prior to the consummation of the initial Business Combination, including interest but less taxes payable. The decision as to whether the Company will seek stockholder approval of the Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval unless a vote is required. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the outstanding shares of common stock voted are voted in favor of the Business Combination. However, in no event will the Company redeem its public shares in an amount that would cause its net tangible assets to be less than $5,000,001. In such case, the Company would not proceed with the redemption of its public shares and the related Business Combination, and instead may search for an alternate Business Combination. Additionally, the Company’s initial stockholders, officers and directors have entered into letter agreements with the Company, pursuant to which they have agreed (i) to waive their redemption rights with respect to their founder shares and public shares in connection with the completion of an initial Business Combination and (ii) to waive their rights to liquidating distributions from the trust account with respect to their founder shares if the Company fails to complete its initial Business Combination within 24 months from the closing date of the Public Offering (although they will be entitled to liquidating distributions from the trust account with respect to any public shares they hold if the Company fails to complete an Business Combination within the prescribed time frame). If the Company submits an initial Business Combination to its public stockholders for a vote, the Company’s initial stockholders have agreed to vote their founder shares and any public shares purchased in favor of an initial Business Combination. If the Company holds a stockholder vote or there is a tender offer for shares in connection with a Business Combination, a public stockholder will have the right to redeem its shares for an amount in cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account as of two business days prior to the consummation of the initial Business Combination, including interest but less taxes payable. As a result, such shares of common stock are recorded at redemption amount and classified as temporary equity, in accordance with Accounting Standards Codification (‘‘ASC’’) 480, ‘‘Distinguishing Liabilities from Equity.’’ The amount in the Trust Account was initially $10.10 per Public Share ($174,225,000 held in the Trust Account divided by 17,250,000 Public Shares). If the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions in connection with a Business Combination pursuant to the tender offer rules, the Company’s Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a ‘‘group’’ (as defined under Section 13 of the Exchange Act) will be restricted from redeeming its shares with respect to more than an aggregate of 10% of the shares sold in the Public Offering (‘‘Excess Shares’’). However, the Company would not be restricting the stockholders’ ability to vote all of their shares (including Excess Shares) for or against a Business Combination. The Company will only have 24 months from the closing date of the Public Offering to complete its initial Business Combination. If the Company does not complete a Business Combination within this period of time, it shall (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the Public Shares for a per share pro rata portion of the Trust Account, including interest, but less taxes payable (less up to $50,000 of such net interest to pay dissolution expenses) and (iii) as promptly as possible following such redemption, dissolve and liquidate the balance of the Company’s net assets to its remaining stockholders, as part of its plan of dissolution and liquidation. The sponsor has entered into letter agreements with us, pursuant to which they have waived their rights to participate in any redemption with respect to their founder shares; however, if the sponsor or any of the Company’s officers, directors or affiliates acquire Public Shares in or after the Public Offering, they will be entitled to a pro rata share of the Trust Account upon the Company’s redemption or liquidation in the event the Company does not complete a Business Combination within the required time period. In the event of such distribution, it is possible that the per share value of the Trust Account remaining available for distribution will be less than the public offering price per Unit in the Proposed Offering. In order to protect the amounts held in the Trust Account, the Company’s Chairman and Chief Executive Officer has agreed that he will be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account below $10.10 per share. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act. Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, then the Company’s Chairman and Chief Executive Officer will not be responsible to the extent of any liability for such third party claims. The Trust Account The proceeds held in the Trust account will be invested only in U.S. government treasury bills with a maturity of one hundred eighty (180) days or less in money market funds that meet certain conditions under Rule 2a-7 under the Investment Company of 1940 and that invest only in direct U.S. government obligations. Funds will remain in the Trust Account until the earlier of (i) the consummation of the initial Business Combination or (ii) the distribution of the Trust Account proceeds as described above. The Company’s certificate of incorporation provides that, other than the withdrawal of interest to pay taxes, if any, none of the funds held in the Trust Account will be released to us until the earlier of: (i) the completion of the initial Business Combination; (ii) the redemption of any shares of common stock included in the Units sold in the Public Offering that have been properly tendered in connection with a stockholder vote to amend the Company’s certificate of incorporation to modify the substance or timing of its obligation to redeem 100% of such shares of common stock if it does not complete the initial Business Combination within 24 months from the closing of the Public Offering; and (iii) the redemption of 100% of the shares of common stock included in the Units sold in the Public Offering if the Company is unable to complete an initial Business Combination within 24 months from the closing of the Public Offering (subject to the requirements of law). The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public stockholders. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Sep. 30, 2019 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited interim condensed financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (‘‘U.S. GAAP’’) and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (‘‘SEC’’), and reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position as of September 30, 2019 and the results of operations and cash flows for the periods presented. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. Interim results are not indicative of results for a full year. The unaudited interim condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC on March 26, 2019, which contains the audited financial statements and notes thereto for such fiscal year. Liquidity As of September 30, 2019, the Company had $56,180 in cash held outside of the Trust Account, $4,459,078 in interest income available from the Company’s investments in the Trust Account to pay its franchise and income taxes payable, and current liabilities of $198,608. Further, the Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. The Sponsor has committed to provide up to an aggregate of $1,000,000 in loans to the Company, of which $150,000 has been drawn as of September 30, 2019. Based on the foregoing, the Company expects that it will have sufficient resources to fund its operations until March 20, 2020, its mandatory liquidation date. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. Loss Per Common Share Basic loss per common share is computed by dividing net income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Consistent with ASC 480, common stock subject to possible redemption, as well as their pro rata share of undistributed trust earnings consistent with the two-class method, have been excluded from the calculation of loss per common share for the three and nine months ended September 30, 2019 and 2018. Such shares, if redeemed, only participate in their pro rata share of trust earnings. Diluted loss per share includes the incremental number of shares of common stock to be issued to settle warrants, as calculated using the treasury method. For the three and nine months ended September 30, 2019 and 2018, the Company did not have any dilutive warrants, securities or other contracts that could potentially, be exercised or converted into common stock, since the exercise of the warrants is contingent on the occurrence of future events. As a result, diluted loss per common share is the same as basic loss per common share for all periods presented. A reconciliation of net loss per common share as adjusted for the portion of income that is attributable to common stock subject to redemption is as follows: Three months ended, September 30, Nine months ended, September 30, 2019 2018 2019 2018 Net income (loss) $ 406,454 $ 499,704 $ 1,812,043 971,731 Less: Income attributable to common stock subject to possible redemption (643,594 ) (589,444 ) (2,245,187 ) (1,202,610 ) Net loss available to common shares $ (237,140 ) $ (89,740 ) $ (433,144 ) $ (230,879 ) Basic and diluted weighted average number of shares 5,667,754 5,629,138 5,658,379 5,239,246 Basic and diluted loss available to common shares $ (0.04 ) $ (0.02 ) $ (0.08 ) $ (0.04 ) Concentration of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Cash and cash equivalents: The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2019 and December 31, 2018. Cash and Marketable Securities held in Trust Account: The amounts held in the Trust Account represent proceeds from the Public Offering, the Private Placement, the Sponsor Loan, and accumulated earnings thereon totaling $178,739,627, of which $178,513,131 were invested in United States treasury obligations with original maturities of six months or less. The remaining $226,496 of proceeds were held in cash and money market mutual funds. These assets can only be used by the Company in connection with the consummation of an initial Business Combination, except that interest earned on the Trust Account can be released to the Company to pay its tax obligations. During the three and nine months ended September 30, 2019, the Company withdrew $285,000 and $767,848 to pay its tax obligations, respectively. Common stock subject to possible redemption: The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of events not solely within the Company’s control) is classified as temporary equity and is measured at redemption value. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. Offering Costs The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Bulletin 5A – “Expenses of Offering.” Offering costs were $10,937,331 (including underwriting commission of $3,000,000 and deferred underwriting commissions of $7,350,000), consisting principally of costs incurred in connection with preparation for the Public Offering. These offering costs were charged to additional paid in capital upon closing of the Public Offering. Fair Value of Financial Instruments: The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, ‘‘Fair Value Measurements and Disclosures,’’ approximates the carrying amounts represented in the balance sheet primarily due to their short term nature. Use of Estimates: The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes: The Company complies with the accounting and reporting requirements of ASC 740, ‘‘Income Taxes,’’ which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts and are based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no uncertain tax benefits as of September 30, 2019 and 2018. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at September 30, 2019 and 2018. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by U.S. federal, U.S. states or foreign jurisdiction authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Under ASC 740, Accounting for Income Taxes The effective income tax rate for the three and nine months ended September 30, 2019 was 28% and 22%, respectively. The income tax expense for the three and nine months ended September 30, 2019 differs from the amount that would be expected after applying the statutory income tax rate primarily due to the non-deductibility of transactional costs incurred in connection with the search for potential targets for a Business Combination. Recent Accounting Pronouncements: Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. Subsequent Events Management has evaluated subsequent events to determine if events or transactions occurring through the date the financial statements were issued, require potential adjustment to or disclosure in the financial statements and has concluded that all such events that would require recognition or disclosure have been recognized or disclosed. |
PUBLIC OFFERING
PUBLIC OFFERING | 9 Months Ended |
Sep. 30, 2019 | |
PUBLIC OFFERING [Abstract] | |
PUBLIC OFFERING | NOTE 3 — PUBLIC OFFERING Pursuant to the Public Offering, the Company sold 17,250,000 Units at a price of $10.00 per Unit, including the underwriter over-allotment of 2,250,000 units. Each Unit consists of one share of the Company’s common stock, $0.0001 par value and one redeemable common stock purchase warrant (the ‘‘Warrants’’). Each Warrant entitles the holder to purchase one share of common stock at a price of $11.50. Each Warrant will become exercisable on the completion of the Company’s initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination or earlier upon redemption or liquidation. However, if the Company does not complete its initial Business Combination on or prior to the 24-month period allotted to complete the Business Combination, the Warrants will expire at the end of such period. If the Company is unable to deliver registered shares of common stock to the holder upon exercise of Warrants issued in connection with the 17,250,000 Units during the exercise period, there will be no net cash settlement of these Warrants and the Warrants will expire worthless, unless they may be exercised on a cashless basis in the circumstances described in the warrant agreement. Once the warrants become exercisable, the Company may redeem the outstanding warrants in whole and not in part at a price of $0.01 per warrant upon a minimum of 30 days’ prior written notice of redemption, only in the event that the last sale price of the Company’s shares of common stock equals or exceeds $18.00 per share for any 20 trading days within the 30-trading day period ending on the third trading day before the Company sends the notice of redemption to the warrant holders. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 9 Months Ended |
Sep. 30, 2019 | |
RELATED PARTY TRANSACTIONS [Abstract] | |
RELATED PARTY TRANSACTIONS | NOTE 4— RELATED PARTY TRANSACTIONS Founder Shares In December 2015, the Sponsor purchased 4,312,500 shares of common stock (the ‘‘Founder Shares’’) for $25,000, or approximately $0.006 per share. In December 2017, the Sponsor transferred 15,000 Founder Shares to each of the Company’s independent director nominees. The Founder Shares are identical to the common stock included in the Units sold in the Public Offering except that the Founder Shares are subject to certain transfer restrictions, as described in more detail below. The Sponsor agreed to forfeit up to 562,500 Founder Shares to the extent that the over-allotment option was not exercised in full by the underwriters. As a result of the underwriters’ over-allotment exercise in full, no shares are currently subject to forfeiture. The Company’s initial stockholders’ have agreed not to transfer, assign or sell any of their Founder Shares until the earlier of (A) one year after the completion of the Company’s initial Business Combination, or (B) the date on which the Company completes a liquidation, merger, stock exchange or other similar transaction after the initial Business Combination that results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property (the ‘‘Lock Up Period’’). If subsequent to the Company’s initial Business Combination, the last sale price of the Company’s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company’s initial Business Combination, or if the Company consummates a transaction after the initial Business Combination which results in the stockholders having the right to exchange their shares for cash, securities, or other property, the Founder Shares will be released from the lock-up. Placement Warrants The Sponsor purchased from the Company an aggregate of 4,500,000 warrants at a price of $1.00 per warrant (a purchase price of $4,500,000), in the Private Placement that occurred simultaneously with the completion of the Public Offering. Each Placement Warrant entitles the holder to purchase one share of common stock at $11.50 per share. The purchase price of the Placement Warrants was added to the proceeds from the Public Offering held in the Trust Account pending completion of the Company’s initial Business Combination. The Placement Warrants (including the common stock issuable upon exercise of the Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination and they will be non-redeemable so long as they are held by the Sponsor or its permitted transferees. If the Placement Warrants are held by someone other than the Sponsor or its permitted transferees, the Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the warrants included in the Units sold in the Public Offering. Otherwise, the Placement Warrants have terms and provisions that are identical to those of the Warrants sold as part of the Units in the Public Offering and have no net cash settlement provisions. If the Company does not complete a Business Combination, then the proceeds will be part of the liquidating distribution to the public stockholders and the Warrants issued to the Sponsor will expire worthless. Related Party Loans The Company’s Sponsor loaned the Company an aggregate of $250,000 against the issuance of an unsecured promissory note (the ‘‘Note’’) to cover expenses related to this Public Offering. This loan was repaid during the quarter ended June 30, 2018. Additionally, the Company’s Sponsor paid, on behalf of the Company, a total of $69,540 for costs related to the Public Offering in excess of the Note, which was repaid out of working capital during the quarter ended September 30, 2018. Our Sponsor has extended a loan to the Company in the amount of $1,725,000, inclusive of $225,000 as a result of the exercise of the underwriter’s over-allotment option, which is non-interest bearing and which will become due upon the completion of a Business Combination. In addition, in order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required. If the Company completes its Business Combination, the Company would repay such loaned amounts out of the proceeds of the Trust Account released to it. Otherwise, such loans would be repaid only out of funds held outside the Trust Account. In the event that the Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used to repay such loaned amounts. Up to $2,000,000 of such loans (including the loan from our Sponsor) may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Placement Warrants discussed above, though the Sponsor loan warrants would be identical to the public warrants, except that they would not be redeemable by the Company and would be exercisable on a cashless basis. Other than the currently existing loan from our Sponsor, the terms of such loans by the Company’s Sponsor, officers and directors, if any, have not been determined and no written agreements exist with respect to such loans. In August 2019, we issued an unsecured promissory note in the amount of $1,000,000 to the Sponsor. As of September 30, 2019, we borrowed $150,000 under such note for working capital purposes. The note bears no interest and is repayable in full upon the earlier of consummation of the Company’s initial business combination and its winding up. The note may be converted into Warrants at a conversion price of $1.00 per Warrant at the Sponsor’s discretion. Each Warrant would be identical to the Placement Warrants discussed above. Commencing March 2018, the Company agreed to pay its Chief Investment Officer $12,500 per month until the earlier of liquidation or the consummation of an initial Business Combination. The Company paid a total of $37,500 and $112,500 during the three and nine months ended September 30, 2019, respectively. The Company paid a total of $37,500 and $75,000 during the three and nine months ended September 30, 2018, respectively. In addition, an amount of $6,250 is included in Accounts payable and accrued expenses as of September 30, 2019. In March 2018, the Company entered into an Administrative Services Agreement pursuant to which it pays its Sponsor, an affiliate of our Executive Chairman and Chief Executive Officer, a total of $10,000 per month for office space, utilities and secretarial support. Upon completion of our initial Business Combination or liquidation, the Company will cease paying these monthly fees. The Company paid a total of $30,000 and $60,000 during the three and nine months ended September 30, 2018, respectively. The Company did not pay any amounts pursuant to this agreement during the three and nine months ended September 30, 2019. As a result of such non-payment, an amount of $95,000 is included in Due to Sponsor as of September 30, 2019. |
CASH AND MARKETABLE SECURITIES
CASH AND MARKETABLE SECURITIES IN TRUST ACCOUNT | 9 Months Ended |
Sep. 30, 2019 | |
CASH AND MARKETABLE SECURITIES IN TRUST ACCOUNT [Abstract] | |
CASH AND MARKETABLE SECURITIES IN TRUST ACCOUNT | NOTE 5 — CASH AND MARKETABLE SECURITIES IN TRUST ACCOUNT Upon the closing of the Public Offering, the Private Placement, and the Sponsor Loan, $174,225,000 was placed in the Trust Account. At September 30, 2019, the Company’s Trust Account consisted of $226,496 of cash and money market mutual funds and $178,513,131 in United States treasury obligations with maturities of one hundred and eighty (180) days or less. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 9 Months Ended |
Sep. 30, 2019 | |
FAIR VALUE MEASUREMENTS [Abstract] | |
FAIR VALUE MEASUREMENTS | NOTE 6 — FAIR VALUE MEASUREMENTS The following table presents information about the Company’s assets that are measured on a recurring basis as of September 30, 2019 and December 31, 2018 indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability. September 30, 2019 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Investments in United States treasury obligations held in Trust Account $ 178,513,131 $ 178,513,131 $ - $ - Total $ 178,513,131 $ 178,513,131 $ - $ - December 31, 2018 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Investments in United States treasury obligations held in Trust Account $ 176,444,135 $ 176,444,135 $ - $ - Total $ 176,444,135 $ 176,444,135 $ - $ - |
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY | 9 Months Ended |
Sep. 30, 2019 | |
STOCKHOLDERS' EQUITY [Abstract] | |
STOCKHOLDERS' EQUITY | NOTE 7 — STOCKHOLDERS’ EQUITY Common Stock The authorized common stock of the Company includes up to 60,000,000 shares with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share of common stock. At September 30, 2019, there were 5,690,730 shares of common stock issued and outstanding (excluding 15,871,770 shares of common stock subject to redemption). At December 31, 2018, there were 5,648,372 shares of common stock issued and outstanding (excluding 15,914,128 shares of common stock subject to redemption). Preferred Stock The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Board of Directors. At September 30, 2019 and December 31, 2018, there were no shares of preferred stock issued and outstanding. Warrants The warrants will become exercisable on the later of (a) 30 days after the completion of our initial Business Combination, and (b) 12 months from the closing of the Public Offering; provided in each case that we have an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or we permit holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement). The Company did not register the shares of common stock issuable upon exercise of the warrants. However, the Company has agreed that as soon as practicable, but in no event later than thirty (30) days after the closing of an initial Business Combination, the Company will use its best efforts to file with the SEC and have an effective registration statement covering the shares of common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of common stock until the warrants expire or are redeemed. If a registration statement covering the shares of common stock issuable upon exercise of the warrants is not effective within 90 days after the closing of an initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis. The warrants will expire at 5:00 p.m., New York City time, five years after the completion of an initial Business Combination or earlier upon redemption or liquidation. On the exercise of any warrant, the warrant exercise price will be paid directly to the Company and not placed in the trust account. Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the private placement warrants or sponsor loan warrants): • in whole and not in part; • at a price of $0.01 per warrant; upon a minimum of 30 days’ prior written notice of redemption, referred to as the 30-day redemption period; and • if, and only if, the last sale price of the Company’s common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. The Company will not redeem the warrants unless a registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of common stock is available throughout the 30-day redemption period. If the Company calls the warrants for redemption as described above, its management will have the option to require all holders that wish to exercise warrants to do so on a ‘‘cashless basis.’’ In determining whether to require all holders to exercise their warrants on a ‘‘cashless basis,’’ its management will consider, among other factors, cash position, the number of warrants that are outstanding and the dilutive effect on stockholders of issuing the maximum number of shares of common stock issuable upon the exercise of warrants. In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the ‘‘fair market value’’ (defined below) by (y) the fair market value. The ‘‘fair market value’’ shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. None of the Placement Warrants or sponsor loan warrants will be redeemable by the Company so long as they are held by the Company’s Sponsor or its permitted transferees. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Sep. 30, 2019 | |
COMMITMENTS AND CONTINGENCIES [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 8 — COMMITMENTS AND CONTINGENCIES Underwriting Agreement The Company paid an underwriting discount of 2% of the per Unit offering price to the underwriters at the closing of the Public Offering, excluding any amounts raised pursuant to the over-allotment option, or $3,000,000. In addition, the Underwriter is entitled to an aggregate deferred underwriting discount of $7,350,000 consisting of (i) four percent (4%) of the gross proceeds of the Public Offering, excluding any amounts raised pursuant to the over-allotment option, and (ii) six percent (6%) of the gross proceeds of the Units sold in the Public Offering pursuant to the over-allotment option. The Deferred Discount will be waived by the underwriters if the Company fails to complete a Business Combination and liquidates. Registration Rights Pursuant to a registration rights agreement entered into on March 15, 2018, the holders of the Company’s Founder Shares, holders of the Placement Warrants and holders of any warrants issued to the sponsor on conversion of the Sponsor’s loan at its discretion (and any shares of common stock issuable upon the exercise of such warrants, respectively) are entitled to registration rights. The Company’s Sponsor, holders of the Placement Warrants and holders of any warrants issued to the Sponsor on conversion of the Sponsor’s loan at its discretion (and any shares of common stock issuable upon the exercise of such warrants, respectively) are entitled to make up to three demands, excluding short form registration demands, that the Company register such securities for sale under the Securities Act. In addition, these holders have ‘‘piggy-back’’ registration rights to include their securities in other registration statements filed by the Company. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The registration rights agreement does not provide for any cash penalties or additional penalties associated with any delays in registering the securities. Forward Purchase Contracts An anchor investor has committed, pursuant to a forward purchase contract with the Company, to purchase, in a private placement for gross proceeds of $15,000,000 to occur concurrently with the consummation of its initial Business Combination, 1,500,000 of the Company’s units at $10.00 per unit, and 300,000 shares of Common Stock (which will have the same terms as the Founder Shares described herein, except that they shall be for no additional consideration). The funds from the sale of units will be used as part of the consideration to the sellers in the initial Business Combination or for the combined company’s working capital needs. This commitment is independent of the percentage of stockholders electing to redeem their public shares and provides the Company with a minimum funding level for the initial Business Combination or future working capital needs. Co-anchor investors have also committed, pursuant to forward purchase contracts with the Company, to purchase, in a private placement for gross proceeds of $10,000,000 to occur concurrently with the consummation of its initial Business Combination, 1,000,000 shares of Common Stock at a purchase price of $10.00 per share and 100,000 additional shares of Common Stock; these additional shares shall have the same terms as the Founder Shares, except that they shall be for no additional consideration. The funds from the sale of such shares will be used as part of the consideration to the sellers in the initial Business Combination or for the combined company’s working capital needs. This commitment is independent of the percentage of stockholders electing to redeem their public shares and provides the Company with a minimum funding level for the initial Business Combination or future working capital needs. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Sep. 30, 2019 | |
SUBSEQUENT EVENTS [Abstract] | |
SUBSEQUENT EVENTS | NOTE 9 – SUBSEQUENT EVENTS The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the condensed financial statements were issued. Except as described below, the Company did not identify subsequent events that would have required adjustment or disclosure in the condensed financial statements other than the following. On October 10, 2019, the Company entered into the Business Combination Agreement (the “ Business Combination Agreement Closing Purchaser Representative IGI Jabsheh Seller Representative Sellers Pubco Merger Sub In connection with the Business Combination Agreement, on October 10, 2019, certain shareholders of IGI holding approximately 91.4% of the issued and outstanding capital shares of IGI entered into Share Exchange Agreements with IGI, Tiberius and the Seller Representative, pursuant to which Pubco will become a party thereafter upon execution of a joinder thereto (each, an “ Exchange Agreement ”), and other shareholders of IGI may enter into Exchange Agreements after the date of the Business Combination Agreement and prior to the Closing. Pursuant to the Business Combination Agreement and the Exchange Agreements, subject to the terms and conditions set forth therein, at the Closing (a) the Company will merge with and into Merger Sub, with the Company continuing as the surviving entity (the “ Merger ”), and with all holders of the Company’s securities receiving substantially identical securities of Pubco, and (b) Pubco will acquire all or substantially all of the issued and outstanding ordinary shares of IGI (the “ Purchased Shares ”) from the Sellers in exchange for a mix of cash and ordinary shares of Pubco, with IGI becoming a subsidiary of Pubco (the “ Share Exchange ”, and together with the Merger and the other transactions contemplated by the Business Combination Agreement, the “ Business Combination ”). The total consideration to be paid by Pubco to the Sellers for the Purchased Shares (the “ Transaction Consideration ”) will be equal to (i) the sum of (the “ Adjusted Book Value ”) (A) the total consolidated book equity value of IGI and its subsidiaries as of the most recent month end of IGI prior to the Closing (the “ Book Value ”), plus (B) the amount of IGI’s out-of-pocket transaction expenses which reduced the Book Value from what it would have been if such expenses had not been incurred, multiplied by (ii) 1.22, and multiplied by (iii) a fraction equal to (A) the total number of Purchased Shares divided by (B) the total number of issued and outstanding IGI ordinary shares as of the Closing. $80,000,000 of the Transaction Consideration will be paid in cash (the “ Cash Consideration The remaining Transaction Consideration will be paid by Pubco to the Sellers by delivery of newly issued ordinary shares of Pubco (the “ Exchange Shares ”) equal in value to the Transaction Consideration less the Cash Consideration (the “ Equity Consideration ”), with each Exchange Share valued at the price per share (the “ Redemption Price ”) at which each share of the Company’s common stock is redeemed or converted pursuant to the redemption by the Company of its public stockholders in connection with the Company’s initial business combination, as required by its amended and restated certificate of incorporation and the Company’s initial public offering prospectus . The Exchange Shares will be allocated among the Sellers pro rata based on the total number of Purchased Shares held by them after deducting the number of Purchased Shares paid for with the Cash Consideration. A number of Exchange Shares otherwise issuable to the Sellers at the Closing equal to 2.5% of the Transaction Consideration (the “ Escrow Shares ”) will be set aside in escrow and delivered to Continental Stock Transfer & Trust Company (or such other escrow agent reasonably acceptable to the Company and IGI), as escrow agent , at the Closing, with such Escrow Shares, and any dividends, distributions or other earnings thereon, to be used as the sole source of remedy available to Pubco for any post-closing Transaction Consideration negative adjustments. The Escrow Shares will be allocated among the Sellers pro rata based on the number of Exchange Shares received by each Seller, and while held in escrow, each Seller will have voting rights on the Escrow Shares based on such allocation. The Transaction Consideration to be paid by Pubco at the Closing will be based off of an estimate of the most current month-end Adjusted Book Value at the Closing and subject to a post-Closing true-up. If the true-up results in a decrease in the Transaction Consideration, such true-up will be paid to Pubco by delivery of the Escrow Shares (which will be effectively cancelled by Pubco) and other escrow property based on a price per share equal to the Redemption Price. If the true-up results in an increase in the Transaction Consideration, such true-up will be paid by Pubco by delivery of additional Exchange Shares based on a price per share equal to the Redemption Price (and without a cap on the number of additional Exchange Shares to be issued). Upon the final determination of the true-up, any remaining Escrow Shares or other escrow property will be delivered to the Sellers. Simultaneously with the execution of the Business Combination Agreement on October 10, 2019, Tiberius entered into subscription agreements (each, a “ Subscription Agreement ”) with certain investors (the “ PIPE Investors ”), pursuant to which Tiberius agreed to issue and sell to the PIPE Investors an aggregate of $23,611,809 of Tiberius common stock at $10.20 per share immediately prior to, and subject to, the Closing, which will become Pubco common shares in the Merger. The Subscription Agreement investment is conditioned on the concurrent Closing and other customary closing conditions. The PIPE Investors were also given registration rights in the Subscription Agreements pursuant to which Pubco, as the successor to Tiberius will be required to file a resale registration statement for the shares issued to the PIPE Investors within 30 days after the Closing and use its commercially reasonable efforts to have the registration statement declared effective as soon as practicable after the filing thereof. Each PIPE Investor agreed in the Subscription Agreement that it and its affiliates will not have any right, title, interest or claim of any kind in or to any monies in Tiberius’ trust account held for its public shareholders, and agreed not to, and waived any right to, make any claim against the trust account (including any distributions therefrom). The proceeds from the Subscription Agreement investment will be used to fund a portion of the cash consideration for the Business Combination, the transaction expenses and other liabilities of Tiberius and otherwise provide working capital and funds for corporate purposes to Pubco after the Closing. Simultaneously with the execution of the Business Combination Agreement on October 10, 2019, Tiberius entered into subscription agreements (each, a “ Backstop Subscription Agreement Backstop Investors Simultaneously with the execution of the Business Combination Agreement on October 10, 2019, Tiberius entered into a Waiver Agreement (the “ Waiver Agreement ”) with its existing shareholder Weiss Multi-Strategy Advisers LLC (“ Weiss ”), pursuant to which Weiss agreed to waive any redemption rights that it might have with respect to the 1,327,700 shares of Tiberius common stock that it owns with respect to the Business Combination, and not to transfer, grant any proxies or powers of attorney or incur any liens with respect to, any such shares prior to the Closing. The Waiver Agreement will automatically terminate pursuant to its terms upon a termination of the Business Combination Agreement. The Waiver Agreement will help to ensure that Tiberius retains sufficient funds in its trust account to meet the Minimum Cash Condition. Simultaneously with the execution of the Business Combination Agreement on October 10, 2019, Tiberius and Cantor Fitzgerald & Co. (“ Cantor Underwriting Agreement Amendment Underwriting Agreement Deferred Commission Shares Simultaneously with the execution of the Business Combination Agreement on October 10, 2019, Tiberius entered into a Warrant Purchase Agreement (the “ Warrant Purchase Agreement ”) with Church Mutual Insurance Company (“ Church ”), pursuant to which Tiberius agreed to purchase from Church and Church agreed to sell to Tiberius, simultaneously with and subject to the Closing (but after giving effect to the Forward Purchase Contract that was entered into between Tiberius and Church on November 9, 2017 (the “ Church Forward Purchase Contract ”)), 3,000,000 of the Tiberius warrants owned by Church, with 1,500,000 of such warrants currently owned by Church and 1,500,000 of such warrants to be issued to Church at the Closing pursuant to the Church Forward Purchase Contract (and including in each case any successor Pubco warrants upon the Merger), at $0.75 per warrant, for an aggregate purchase price of $2,250,000. Church agreed that until the Closing or earlier termination of the Warrant Purchase Agreement, it will not transfer any of its Tiberius warrants. Church also confirmed that IGI does not operate in an industry in which Church is prohibited from investing pursuant to the Church’s internal written policies and waived the conditions of the Church Forward Purchase Contract with respect thereto. The Warrant Purchase Agreement will automatically terminate pursuant to its terms upon a termination of the Business Combination Agreement. Church agreed in the Warrant Purchase Agreement that it and its affiliates will not have any right, title, interest or claim of any kind in or to any monies in Tiberius’ trust account held for its public shareholders, and agreed not to, and waived any right to, make any claim against the trust account (including any distributions therefrom). |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Sep. 30, 2019 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
Basis of Presentation | Basis of Presentation The unaudited interim condensed financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (‘‘U.S. GAAP’’) and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (‘‘SEC’’), and reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position as of September 30, 2019 and the results of operations and cash flows for the periods presented. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. Interim results are not indicative of results for a full year. The unaudited interim condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC on March 26, 2019, which contains the audited financial statements and notes thereto for such fiscal year. |
Liquidity | Liquidity As of September 30, 2019, the Company had $56,180 in cash held outside of the Trust Account, $4,459,078 in interest income available from the Company’s investments in the Trust Account to pay its franchise and income taxes payable, and current liabilities of $198,608. Further, the Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. The Sponsor has committed to provide up to an aggregate of $1,000,000 in loans to the Company, of which $150,000 has been drawn as of September 30, 2019. Based on the foregoing, the Company expects that it will have sufficient resources to fund its operations until March 20, 2020, its mandatory liquidation date. |
Loss Per Common Share | Loss Per Common Share Basic loss per common share is computed by dividing net income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Consistent with ASC 480, common stock subject to possible redemption, as well as their pro rata share of undistributed trust earnings consistent with the two-class method, have been excluded from the calculation of loss per common share for the three and nine months ended September 30, 2019 and 2018. Such shares, if redeemed, only participate in their pro rata share of trust earnings. Diluted loss per share includes the incremental number of shares of common stock to be issued to settle warrants, as calculated using the treasury method. For the three and nine months ended September 30, 2019 and 2018, the Company did not have any dilutive warrants, securities or other contracts that could potentially, be exercised or converted into common stock, since the exercise of the warrants is contingent on the occurrence of future events. As a result, diluted loss per common share is the same as basic loss per common share for all periods presented. A reconciliation of net loss per common share as adjusted for the portion of income that is attributable to common stock subject to redemption is as follows: Three months ended, September 30, Nine months ended, September 30, 2019 2018 2019 2018 Net income (loss) $ 406,454 $ 499,704 $ 1,812,043 971,731 Less: Income attributable to common stock subject to possible redemption (643,594 ) (589,444 ) (2,245,187 ) (1,202,610 ) Net loss available to common shares $ (237,140 ) $ (89,740 ) $ (433,144 ) $ (230,879 ) Basic and diluted weighted average number of shares 5,667,754 5,629,138 5,658,379 5,239,246 Basic and diluted loss available to common shares $ (0.04 ) $ (0.02 ) $ (0.08 ) $ (0.04 ) |
Concentration of Credit Risk | Concentration of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. |
Cash and Cash Equivalents | Cash and cash equivalents: The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2019 and December 31, 2018. |
Cash and Marketable Securities held in Trust Account | Cash and Marketable Securities held in Trust Account: The amounts held in the Trust Account represent proceeds from the Public Offering, the Private Placement, the Sponsor Loan, and accumulated earnings thereon totaling $178,739,627, of which $178,513,131 were invested in United States treasury obligations with original maturities of six months or less. The remaining $226,496 of proceeds were held in cash and money market mutual funds. These assets can only be used by the Company in connection with the consummation of an initial Business Combination, except that interest earned on the Trust Account can be released to the Company to pay its tax obligations. During the three and nine months ended September 30, 2019, the Company withdrew $285,000 and $767,848 to pay its tax obligations, respectively. |
Common Stock Subject to Possible Redemption | Common stock subject to possible redemption: The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of events not solely within the Company’s control) is classified as temporary equity and is measured at redemption value. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. |
Offering Costs | Offering Costs The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Bulletin 5A – “Expenses of Offering.” Offering costs were $10,937,331 (including underwriting commission of $3,000,000 and deferred underwriting commissions of $7,350,000), consisting principally of costs incurred in connection with preparation for the Public Offering. These offering costs were charged to additional paid in capital upon closing of the Public Offering. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments: The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, ‘‘Fair Value Measurements and Disclosures,’’ approximates the carrying amounts represented in the balance sheet primarily due to their short term nature. |
Use of Estimates | Use of Estimates: The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. |
Income Taxes | Income Taxes: The Company complies with the accounting and reporting requirements of ASC 740, ‘‘Income Taxes,’’ which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts and are based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no uncertain tax benefits as of September 30, 2019 and 2018. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at September 30, 2019 and 2018. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by U.S. federal, U.S. states or foreign jurisdiction authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Under ASC 740, Accounting for Income Taxes The effective income tax rate for the three and nine months ended September 30, 2019 was 28% and 22%, respectively. The income tax expense for the three and nine months ended September 30, 2019 differs from the amount that would be expected after applying the statutory income tax rate primarily due to the non-deductibility of transactional costs incurred in connection with the search for potential targets for a Business Combination. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements: Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. |
Subsequent Events | Subsequent Events Management has evaluated subsequent events to determine if events or transactions occurring through the date the financial statements were issued, require potential adjustment to or disclosure in the financial statements and has concluded that all such events that would require recognition or disclosure have been recognized or disclosed. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
Loss Per Common Share | A reconciliation of net loss per common share as adjusted for the portion of income that is attributable to common stock subject to redemption is as follows: Three months ended, September 30, Nine months ended, September 30, 2019 2018 2019 2018 Net income (loss) $ 406,454 $ 499,704 $ 1,812,043 971,731 Less: Income attributable to common stock subject to possible redemption (643,594 ) (589,444 ) (2,245,187 ) (1,202,610 ) Net loss available to common shares $ (237,140 ) $ (89,740 ) $ (433,144 ) $ (230,879 ) Basic and diluted weighted average number of shares 5,667,754 5,629,138 5,658,379 5,239,246 Basic and diluted loss available to common shares $ (0.04 ) $ (0.02 ) $ (0.08 ) $ (0.04 ) |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
FAIR VALUE MEASUREMENTS [Abstract] | |
Assets Measured on Recurring Basis | The following table presents information about the Company’s assets that are measured on a recurring basis as of September 30, 2019 and December 31, 2018 indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability. September 30, 2019 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Investments in United States treasury obligations held in Trust Account $ 178,513,131 $ 178,513,131 $ - $ - Total $ 178,513,131 $ 178,513,131 $ - $ - December 31, 2018 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Investments in United States treasury obligations held in Trust Account $ 176,444,135 $ 176,444,135 $ - $ - Total $ 176,444,135 $ 176,444,135 $ - $ - |
DESCRIPTION OF ORGANIZATION A_2
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details) - USD ($) | Mar. 28, 2018 | Mar. 20, 2018 | Mar. 31, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 |
Organization and General [Abstract] | ||||||
Number of units sold in public offering (in shares) | 17,250,000 | |||||
Gross proceeds from units sold in public offering | $ 0 | $ 169,500,000 | ||||
Private placement warrants sold (in shares) | 4,500,000 | |||||
Proceeds from warrants sold | 0 | $ 4,500,000 | ||||
Loan from sponsor | $ 225,000 | $ 1,500,000 | 1,875,000 | $ 1,725,000 | ||
Net proceeds placed in Trust Account | $ 174,225,000 | |||||
Units sold in public offering price per unit (in dollars per share) | $ 10.10 | |||||
Transaction costs | $ 10,937,331 | |||||
Underwriting fees | 3,000,000 | |||||
Deferred underwriting fees | 7,350,000 | $ 7,350,000 | ||||
Public offering costs | 587,331 | |||||
Cash held outside of Trust Account | $ 1,278,124 | |||||
Business Combinations [Abstract] | ||||||
Minimum percentage fair value target business in trust account balance | 80.00% | |||||
Number of business days in which cash needs to be deposited prior to business combination | 2 days | |||||
Net tangible assets | $ 5,000,001 | |||||
Period to complete initial business combination | 24 months | |||||
Percentage of excess shares to be restricted from redeeming | 10.00% | |||||
Minimum period to redeem public shares of common stock | 10 days | |||||
Interest on dissolution expenses | $ 50,000 | |||||
Trust Account [Abstract] | ||||||
Percentage of common stock to be redeemed in case of not completing business combination | 100.00% | |||||
Maximum [Member] | ||||||
Trust Account [Abstract] | ||||||
Maturity period of treasury bills | 180 days | |||||
Public Offering [Member] | ||||||
Organization and General [Abstract] | ||||||
Number of units sold in public offering (in shares) | 15,000,000 | |||||
Gross proceeds from units sold in public offering | $ 150,000,000 | |||||
Net proceeds placed in Trust Account | $ 151,500,000 | |||||
Units sold in public offering price per unit (in dollars per share) | $ 10.10 | |||||
Placement [Member] | ||||||
Organization and General [Abstract] | ||||||
Private placement warrants sold (in shares) | 4,500,000 | |||||
Warrants sold (in dollars per share) | $ 1 | |||||
Proceeds from warrants sold | $ 4,500,000 | |||||
Over-Allotment Option [Member] | ||||||
Organization and General [Abstract] | ||||||
Number of units sold in public offering (in shares) | 2,250,000 | 2,250,000 | ||||
Net proceeds placed in Trust Account | $ 22,725,000 | |||||
Units sold in public offering price per unit (in dollars per share) | $ 10 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | ||
Liquidity [Abstract] | ||||||||||
Cash held outside of the Trust Account | $ 56,180 | $ 56,180 | $ 325,115 | |||||||
Interest income from investments in Trust Account | 4,459,078 | |||||||||
Current liabilities | 198,608 | 198,608 | 189,237 | |||||||
Maximum loan commitment by sponsor | 1,000,000 | 1,000,000 | ||||||||
Amount drawn | $ 150,000 | $ 150,000 | ||||||||
Loss Per Common Share [Abstract] | ||||||||||
Antidilutive warrants, securities and other contracts excluded from computation of earnings per share (in shares) | 0 | 0 | 0 | 0 | ||||||
Net income (loss) | $ 406,454 | $ 762,649 | $ 642,940 | $ 499,704 | $ 459,641 | $ 12,386 | $ 1,812,043 | $ 971,731 | ||
Less: Income attributable to common stock subject to possible redemption | (643,594) | (589,444) | (2,245,187) | (1,202,610) | ||||||
Net loss available to common shares | $ (237,140) | $ (89,740) | $ (433,144) | $ (230,879) | ||||||
Basic and diluted weighted average number of shares (in shares) | [1] | 5,667,754 | 5,629,138 | 5,658,379 | 5,239,246 | |||||
Basic and diluted loss available to common shares (in dollars per share) | [2] | $ (0.04) | $ (0.02) | $ (0.08) | $ (0.04) | |||||
Concentration of Credit Risk [Abstract] | ||||||||||
Federal depository insurance coverage | $ 250,000 | $ 250,000 | ||||||||
Cash and Marketable Securities Held in Trust Account [Abstract] | ||||||||||
Amount held in trust account | 178,739,627 | 178,739,627 | 176,444,379 | |||||||
Investments in United States treasury obligations held in Trust Account | 178,513,131 | $ 178,513,131 | ||||||||
Original maturity of amount held in trust account | 6 months | |||||||||
Proceeds held in cash and money market mutual funds | 226,496 | $ 226,496 | ||||||||
Withdrawn amount for income tax obligation | 285,000 | 767,848 | ||||||||
Offering Cost [Abstract] | ||||||||||
Offering costs | 10,937,331 | |||||||||
Underwriting commission | 3,000,000 | |||||||||
Deferred underwriting commissions | 7,350,000 | 7,350,000 | $ 7,350,000 | |||||||
Income Taxes [Abstract] | ||||||||||
Uncertain tax benefits | 0 | $ 0 | 0 | $ 0 | ||||||
Interest and penalties related to unrecognized tax benefits | $ 0 | $ 0 | $ 0 | $ 0 | ||||||
Corporate tax rate | 21.00% | 35.00% | ||||||||
Effective income tax rate | 28.00% | 22.00% | ||||||||
[1] | Excludes an aggregate of 15,871,770 and 15,924,510 shares subject to redemption at September 30, 2019 and 2018, respectively. | |||||||||
[2] | Net loss per common share - basic and diluted excludes interest income attributable to common stock subject redemption of $643,594 and $589,444 for the three months ended September 30, 2019 and 2018, respectively, and $2,245,187 and $1,202,610 for the nine months ended September 30, 2019 and 2018, respectively. |
PUBLIC OFFERING (Details)
PUBLIC OFFERING (Details) - $ / shares | Mar. 28, 2018 | Sep. 30, 2019 | Dec. 31, 2018 |
Public Offering [Abstract] | |||
Number of units sold in public offering (in shares) | 17,250,000 | ||
Units sold in public offering price per unit (in dollars per share) | $ 10 | ||
Number of common shares consisted by each unit (in shares) | 1 | ||
Units sold in public offering price per unit (in dollars per share) | $ 0.0001 | $ 0.0001 | |
Number of redeemable common shares consisted by each unit (in shares) | 1 | ||
Number of warrants to purchase common shares (in shares) | 1 | ||
Warrant exercise price (in dollars per share) | $ 11.50 | ||
Number of years after completion of Business Combination for warrant expiration | 5 years | ||
Warrants redemption price (in dollars per share) | $ 0.01 | ||
Period of prior written notice to redeem warrants | 30 days | ||
Last sale price of common stock (in dollars per share) | $ 18 | ||
Over-Allotment [Member] | |||
Public Offering [Abstract] | |||
Number of units sold in public offering (in shares) | 2,250,000 | 2,250,000 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details) - USD ($) | Mar. 28, 2018 | Mar. 20, 2018 | Aug. 31, 2019 | Dec. 31, 2017 | Dec. 31, 2015 | Sep. 30, 2019 | Sep. 30, 2018 | Mar. 31, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 |
Founder Shares [Abstract] | |||||||||||
Additional shares of Common Stock in Business Combination (in shares) | 17,250,000 | ||||||||||
Founder Shares purchase price | $ 161,562,670 | ||||||||||
Founder Shares price per share (in dollars per share) | $ 10.10 | $ 10.10 | |||||||||
Sale price of common stock (in dollars per share) | $ 18 | $ 18 | |||||||||
Placement Warrants [Abstract] | |||||||||||
Warrants purchase price | $ 0 | $ 4,500,000 | |||||||||
Number of warrants to purchase common shares (in shares) | 1 | 1 | |||||||||
Warrant exercise price (in dollars per share) | $ 11.50 | $ 11.50 | |||||||||
Related Party Loans [Abstract] | |||||||||||
Extended loan amount | $ 225,000 | $ 1,500,000 | $ 1,875,000 | $ 1,875,000 | $ 1,725,000 | ||||||
Amount drawn | 150,000 | 150,000 | |||||||||
Accounts payable and accrued expenses | 103,608 | 103,608 | $ 184,237 | ||||||||
Amount paid to related party | $ 0 | 69,540 | |||||||||
Chief Investment Officer [Member] | |||||||||||
Related Party Loans [Abstract] | |||||||||||
Amount payable to related party | 12,500 | ||||||||||
Placement [Member] | |||||||||||
Placement Warrants [Abstract] | |||||||||||
Warrants purchase price | $ 4,500,000 | ||||||||||
Over-allotment [Member] | |||||||||||
Founder Shares [Abstract] | |||||||||||
Additional shares of Common Stock in Business Combination (in shares) | 2,250,000 | 2,250,000 | |||||||||
Founder Shares price per share (in dollars per share) | $ 10 | ||||||||||
Sponsor [Member] | |||||||||||
Founder Shares [Abstract] | |||||||||||
Additional shares of Common Stock in Business Combination (in shares) | 4,312,500 | ||||||||||
Founder Shares purchase price | $ 25,000 | ||||||||||
Founder Shares price per share (in dollars per share) | $ 0.006 | ||||||||||
Period after completion of initial business combination that founder share activity is restricted, subject to certain conditions | 1 year | ||||||||||
Minimum number of days after initial business combination that founder shares can be transferred subject to certain conditions | 150 days | ||||||||||
Related Party Loans [Abstract] | |||||||||||
Unsecured debt | 250,000 | $ 250,000 | |||||||||
Issuance of unsecured promissory note | $ 1,000,000 | ||||||||||
Amount of expenses paid on behalf of company | 69,540 | ||||||||||
Extended loan amount | $ 1,725,000 | $ 1,725,000 | |||||||||
Conversion price per share (in dollars per share) | $ 1 | $ 1 | |||||||||
Amount drawn | $ 150,000 | $ 150,000 | |||||||||
Accounts payable and accrued expenses | 6,250 | 6,250 | |||||||||
Amount paid to related party | 37,500 | $ 37,500 | 112,500 | 75,000 | |||||||
Sponsor [Member] | Administrative Services Agreement [Member] | |||||||||||
Related Party Loans [Abstract] | |||||||||||
Amount payable to related party | 95,000 | 95,000 | |||||||||
Amount paid to related party | $ 0 | $ 30,000 | $ 0 | $ 60,000 | |||||||
Sponsor [Member] | Minimum [Member] | |||||||||||
Founder Shares [Abstract] | |||||||||||
Sale price of common stock (in dollars per share) | $ 12 | $ 12 | |||||||||
Sponsor [Member] | Maximum [Member] | |||||||||||
Related Party Loans [Abstract] | |||||||||||
Loans can be converted into warrants | $ 2,000,000 | ||||||||||
Sponsor [Member] | Director [Member] | |||||||||||
Founder Shares [Abstract] | |||||||||||
Additional shares of Common Stock in Business Combination (in shares) | 15,000 | ||||||||||
Sponsor [Member] | Executive Chairman and Chief Executive Officer [Member] | Administrative Services Agreement [Member] | |||||||||||
Related Party Loans [Abstract] | |||||||||||
Amount payable to related party | $ 10,000 | ||||||||||
Sponsor [Member] | Placement [Member] | |||||||||||
Founder Shares [Abstract] | |||||||||||
Sale price of common stock (in dollars per share) | $ 1 | $ 1 | |||||||||
Placement Warrants [Abstract] | |||||||||||
Number of warrants purchased by sponsor (in shares) | 4,500,000 | 4,500,000 | |||||||||
Warrants purchase price | $ 4,500,000 | ||||||||||
Number of warrants to purchase common shares (in shares) | 1 | 1 | |||||||||
Warrant exercise price (in dollars per share) | $ 11.50 | $ 11.50 | |||||||||
Period after completion of initial business combination that placement warrants transfer, assign or sale | 30 days | ||||||||||
Sponsor [Member] | Over-allotment [Member] | |||||||||||
Founder Shares [Abstract] | |||||||||||
Founder shares forfeited (in shares) | 0 | ||||||||||
Related Party Loans [Abstract] | |||||||||||
Extended loan amount | $ 225,000 | $ 225,000 | |||||||||
Sponsor [Member] | Over-allotment [Member] | Maximum [Member] | |||||||||||
Founder Shares [Abstract] | |||||||||||
Founder shares forfeited (in shares) | 562,500 |
CASH AND MARKETABLE SECURITIE_2
CASH AND MARKETABLE SECURITIES IN TRUST ACCOUNT (Details) | 9 Months Ended |
Sep. 30, 2019USD ($) | |
CASH AND MARKETABLE SECURITIES IN TRUST ACCOUNT [Abstract] | |
Amount placed in Trust Account upon closing | $ 174,225,000 |
Cash and money market mutual funds in Trust Account | 226,496 |
Investments in United States treasury obligations held in Trust Account | $ 178,513,131 |
Maximum maturity period of US Treasury obligation | 180 days |
FAIR VALUE MEASUREMENTS (Detail
FAIR VALUE MEASUREMENTS (Details) - USD ($) | Sep. 30, 2019 | Dec. 31, 2018 |
Assets, Fair Value Disclosure [Abstract] | ||
Investments in United States treasury obligations held in Trust Account | $ 178,513,131 | |
Recurring [Member] | ||
Assets, Fair Value Disclosure [Abstract] | ||
Investments in United States treasury obligations held in Trust Account | 178,513,131 | $ 176,444,135 |
Total | 178,513,131 | 176,444,135 |
Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | ||
Assets, Fair Value Disclosure [Abstract] | ||
Investments in United States treasury obligations held in Trust Account | 178,513,131 | 176,444,135 |
Total | 178,513,131 | 176,444,135 |
Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||
Assets, Fair Value Disclosure [Abstract] | ||
Investments in United States treasury obligations held in Trust Account | 0 | 0 |
Total | 0 | 0 |
Recurring [Member] | Significant Other Unobservable Inputs (Level 3) [Member] | ||
Assets, Fair Value Disclosure [Abstract] | ||
Investments in United States treasury obligations held in Trust Account | 0 | 0 |
Total | $ 0 | $ 0 |
STOCKHOLDERS' EQUITY (Details)
STOCKHOLDERS' EQUITY (Details) | 9 Months Ended | |
Sep. 30, 2019Vote$ / sharesshares | Dec. 31, 2018$ / sharesshares | |
Common Stock [Abstract] | ||
Common stock, authorized (in shares) | 60,000,000 | 60,000,000 |
Common stock, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 |
Number of votes per holder | Vote | 1 | |
Common shares issued (in shares) | 5,690,730 | 5,648,372 |
Common shares outstanding (in shares) | 5,690,730 | 5,648,372 |
Common shares subject to redemption (in shares) | 15,871,770 | 15,914,128 |
Preferred Stock [Abstract] | ||
Preferred stock authorized (in shares) | 1,000,000 | 1,000,000 |
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 |
Preferred stock issued (in shares) | 0 | 0 |
Preferred stock outstanding (in shares) | 0 | 0 |
Warrant [Abstract] | ||
Number of months from the closing of the Public Offering when warrants become exercisable | 12 months | |
Number of years after completion of Business Combination when the warrant expires | 5 years | |
Redemption price of outstanding warrants (in dollars per share) | $ / shares | $ 0.01 | |
Redemption period | 30 days | |
Last sale price of common stock (in dollars per share) | $ / shares | $ 18 | |
Number of trading days needed for fair market value | 10 days | |
Minimum [Member] | ||
Warrant [Abstract] | ||
Number of days after the completion of the Business Combination when warrants become exercisable | 30 days | |
Maximum [Member] | ||
Warrant [Abstract] | ||
Number of days after the completion of the Business Combination when warrants become exercisable | 90 days |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details) | 9 Months Ended | |
Sep. 30, 2019USD ($)Demand$ / sharesshares | Dec. 31, 2018USD ($) | |
Underwriting Agreement [Abstract] | ||
Percentage of underwriting discount paid | 2.00% | |
Underwriting commission | $ | $ 3,000,000 | |
Deferred underwriting commissions | $ | $ 7,350,000 | $ 7,350,000 |
Percentage of gross proceeds of units sold in public offerings | 4.00% | |
Percentage of gross proceeds from public offering pursuant to over-allotment | 6.00% | |
Registration Rights [Abstract] | ||
Maximum number of demands sponsor is entitled | Demand | 3 | |
Forward Purchase Contracts [Abstract] | ||
Price per unit (in dollars per share) | $ / shares | $ 10.10 | |
Additional shares of Common Stock in Business Combination (in shares) | 17,250,000 | |
Forward Purchase Contracts [Member] | Anchor Investor [Member] | ||
Forward Purchase Contracts [Abstract] | ||
Gross proceeds | $ | $ 15,000,000 | |
Number of units in Business Combination (in shares) | 1,500,000 | |
Price per unit (in dollars per share) | $ / shares | $ 10 | |
Additional shares of Common Stock in Business Combination (in shares) | 300,000 | |
Forward Purchase Contracts [Member] | Co-Anchor Investors [Member] | ||
Forward Purchase Contracts [Abstract] | ||
Gross proceeds | $ | $ 10,000,000 | |
Number of units in Business Combination (in shares) | 1,000,000 | |
Price per unit (in dollars per share) | $ / shares | $ 10 | |
Additional shares of Common Stock in Business Combination (in shares) | 100,000 |
SUBSEQUENT EVENTS (Details)
SUBSEQUENT EVENTS (Details) | Oct. 10, 2019USD ($)$ / sharesshares | Sep. 30, 2019USD ($)$ / shares | Sep. 30, 2018USD ($) |
Subsequent Event [Line Items] | |||
Sale price of common stock (in dollars per share) | $ / shares | $ 18 | ||
Warrants purchase price | $ 0 | $ 4,500,000 | |
Subsequent Event [Member] | Business Combination Agreement [Member] | International General Insurance Holdings Ltd [Member] | |||
Subsequent Event [Line Items] | |||
Ownership interest | 91.40% | ||
Consideration calculation multiplier | 1.22 | ||
Cash consideration | $ 80,000,000 | ||
Number of times of value used to determine transaction consideration | 2 | ||
Subsequent Event [Member] | Business Combination Agreement [Member] | International General Insurance Holdings Ltd [Member] | Wasef Jabsheh [Member] | |||
Subsequent Event [Line Items] | |||
Cash consideration | $ 65,000,000 | ||
Subsequent Event [Member] | Business Combination Agreement [Member] | International General Insurance Holdings Ltd [Member] | Sellers [Member] | |||
Subsequent Event [Line Items] | |||
Cash consideration | $ 15,000,000 | ||
Percentage of exchange shares issuable to sellers | 2.50% | ||
Subsequent Event [Member] | Subscription Agreement [Member] | PIPE Investors [Member] | |||
Subsequent Event [Line Items] | |||
Common stock agreed to issue | $ 23,611,809 | ||
Sale price of common stock (in dollars per share) | $ / shares | $ 10.20 | ||
Period to file a resale registration statement | 30 days | ||
Subsequent Event [Member] | Backstop Subscription Agreement [Member] | Backstop Investors [Member] | |||
Subsequent Event [Line Items] | |||
Common stock agreed to issue | $ 20,000,000 | ||
Sale price of common stock (in dollars per share) | $ / shares | $ 10.20 | ||
Period to file a resale registration statement | 30 days | ||
Subsequent Event [Member] | Waiver Agreement [Member] | Weiss Multi-Strategy Advisers LLC [Member] | |||
Subsequent Event [Line Items] | |||
Common stock agreed to issue | $ 1,327,700 | ||
Subsequent Event [Member] | Underwriting Agreement Amendment [Member] | Cantor Fitzgerald & Co. [Member] | |||
Subsequent Event [Line Items] | |||
Sale price of common stock (in dollars per share) | $ / shares | $ 10.20 | ||
Period to file a resale registration statement | 30 days | ||
Subsequent Event [Member] | Warrant Purchase Agreement [Member] | Church Mutual Insurance Company [Member] | |||
Subsequent Event [Line Items] | |||
Sale price of common stock (in dollars per share) | $ / shares | $ 0.75 | ||
Number of warrants authorized to be issued (in shares) | shares | 3,000,000 | ||
Number of warrants issued (in shares) | shares | 1,500,000 | ||
Remaining number of warrants to be issued (in shares) | shares | 1,500,000 | ||
Warrants purchase price | $ 2,250,000 |